Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73596357" target="_blank" >RIV/61989592:15110/19:73596357 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.nejm.org/doi/10.1056/NEJMoa1816714" target="_blank" >https://www.nejm.org/doi/10.1056/NEJMoa1816714</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1056/NEJMoa1816714" target="_blank" >10.1056/NEJMoa1816714</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Popis výsledku v původním jazyce

Background The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. Methods In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate.

Název v anglickém jazyce

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Popis výsledku anglicky

Background The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. Methods In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

NEW ENGLAND JOURNAL OF MEDICINE

ISSN

0028-4793

e-ISSN

—

Svazek periodika

380

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

1116-1127

Kód UT WoS článku

000461898400007

EID výsledku v databázi Scopus

—